EnCompass Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EnCompass Technologies is developing the F2 cerebral embolic protection (CEP) system, an investigational device designed to capture debris during TAVR procedures to prevent stroke and other brain injuries. The company's technology aims to offer superior filtration, full coverage of the brain's blood vessels, and enhanced ease of use compared to existing options. With an experienced leadership team from the cardiovascular device industry and FDA conditional IDE approval for a U.S. pilot study, EnCompass is positioned to address a significant unmet need in the growing structural heart market.

CardiovascularNeurology

Technology Platform

Filter+ Flow (F2) cerebral embolic protection system featuring 30μm micropore filtration, full three-vessel coverage of the aortic arch with 360° wall apposition, and a low-profile, self-expanding design for ease of use.

Opportunities

The rapid global growth of TAVR procedures and increasing focus on reducing neurological complications create a large and expanding addressable market for cerebral embolic protection.

Technological differentiation in filtration efficacy and ease of use could allow EnCompass to capture significant market share from established competitors and potentially expand into adjacent cardiac and vascular procedure markets.

Risk Factors

The company faces significant clinical and regulatory risk as its investigational device must prove safety and efficacy in FDA trials.

It also confronts intense competition from well-capitalized, established players with approved products and entrenched commercial relationships in the hospital cardiology space.

Competitive Landscape

The cerebral embolic protection market for TAVR is currently dominated by Boston Scientific's Sentinel device and Edwards Lifesciences' TriGuard. These competitors have first-mover advantage, established clinical data, and extensive sales networks. EnCompass aims to compete on technological grounds, claiming superior filtration, three-vessel coverage stability, and user-friendly design.

More companies in Drug Delivery & Formulation →More companies in United States →